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DOI 10.1016/j.neuron.2007.01.023Pardossi-Piquard et al. (2005) recently
reported that the processing of APP
by the presenilin/g-secretase complex
to release the APP intracellular domain
(AICD) allows the latter to upregulate
the cellular expression of neprilysin.
The authors emphasized the biological
eleganceof thisnovel feedbackmecha-
nism in that a by-product (AICD) of the-
generation of amyloid b protein (Ab)
increases the levels of a protease
(neprilysin) that can then degrade Ab.
Here,wereport thatexperimentssimilar
to those of Pardossi-Piquard et al. did
not provide evidence that neprilysin
levels and activity are regulated by pre-
senilin-mediated processing of APP.
Results
Neprilysin Protein Levels Do Not
Correlate with Presenilin
Genotype and Are Not Rescued
by Presenilin Expression
To examine whether neprilysin protein
levels are regulated by presenilin (PS)expression as reported (Pardossi-
Piquard et al., 2005),mouseembryonic
stem cells genetically devoid of both
PS1andPS2 (BD8cells)were analyzed
by Western blotting (see Methods in
the Supplemental Data available
online). Cells were harvested in Tris
buffer containing either no detergent,
0.5% Triton X-100, or 1% NP40 and
blotted for neprilysin, APP C-terminal
fragments (CTFs), and GAPDH. The
lack of PS expression resulted in no
significant reduction in neprilysin levels
in cells harvested in either Tris buffer
or Tris-1% NP40 buffer compared to
identically prepared wt embryonic
stem cells (PBD8) (Figure 1A). In cells
harvested in Tris-0.5% Triton buffer,
we observed either a modest (Fig-
ure 1A) or no (Figure S1A) reduction in
neprilysin levels. To determinewhether
introduction of presenilin could rescue
this variable andmodest decrease, the
BD8 cells were transiently transfected
with PS1, PS2, or both. TransfectionNeuron 53, Feof PS resulted in the rescue of g-secre-
tase complex formation (PS endo-
proteolysis and enhanced nicastrin
maturation) and activity (reduction in
the elevated APP CTFs) in the BD8
cells (Figure 1B) (Chen et al., 2003;
Kimberly et al., 2002; Leem et al.,
2002). However, neprilysin levels were
unchanged (Figure 1B). When quanti-
fied, neprilysin levels (versus control)
were 93.7% ± 0.2% (SEM), 105.7% ±
1.1%, and 98.6% ± 18.3% for cells
transfected with PS1, PS2, or both,
respectively (p > 0.05 in all cases)
(Figure S1B).
Next, we examined primary mouse
embryonic fibroblasts (MEFs) cultured
from mice genetically lacking PS1,
PS2, or both, using the same source
as those analyzed by Pardossi-Piquard
et al. (Herreman et al., 2003). Neprilysin
levels were reduced in PS dKO cells
ascompared towt (Figure1C).Because
PS1 confers the predominant PS activ-
ity found in g-secretase, it would bebruary 15, 2007 ª2007 Elsevier Inc. 479
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CorrespondenceFigure 1. Neprilysin Protein Levels Do Not Correlate with Presenilin Genotype and Are
Not Elevated by Transfection of Presenilin
(A) Lysates of PS1/2 knockout (BD8) and wt (PBD8) cells were extracted in Tris buffer with no
detergent, 0.5% Triton, or 1% NP40. Protein levels of neprilysin, GAPDH, and APP CTFs were
analyzed by Western blotting. (B) BD8 cells were transiently transfected with PS1, PS2, or both
and their lysates blotted for neprilysin, PS1 NTF, PS2 CTF, nicastrin, APP CTFs, and GAPDH.
(C) MEFs devoid of PS1, PS2, both, or neither (wt) were blotted as in (B). (D) PS dKO MEFs
were transiently transfected with PS1 (n = 6) and levels of neprilysin, PS1 NTF, nicastrin, APP
CTFs, and GAPDH assessed by Western blotting.expected that PS1 KOcells would have
dramatically reduced g-secretase ac-
tivity. Moreover, no mature nicastrin
was detected, and APP CTF levels
were elevated in PS1 KO cells, similar
to what occurred in PS dKO cells. Nev-
ertheless, PS1 KO cells displayed the
highest levels of neprilysin (Figure 1C),
suggesting that the variable levels of
neprilysin among these MEF lines is in-
dependent of PS/g-secretase function
but may be due to clonal variation. To
further determinewhether the reduction
of neprilysin levels in PS dKO MEFs is
due to theabsenceofPS,we transiently
transfectedcellswithPS1andanalyzed
neprilysin levels. Introduction of PS1
was able to rescue g-secretase com-
plex formation and activity, but neprily-
sin levels were unchanged (Figure 1D).
Quantification of two independent
experiments (each with n = 6) revealed
that PS1-transfected cells had neprily-
sin levels that were 105.5% ± 3.6%
(SEM) of control cells (Figure S1C).
Together, these data suggest that the
presence or absence of PS expression
does not affect neprilysin levels in the
examined blastocytes and primary
fibroblasts.480 Neuron 53, February 15, 2007 ª200g-Secretase Inhibition Does Not
Reduce Neprilysin Protein Levels
To examine whether neprilysin levels
are regulated by g-secretase activity,7 Elsevier Inc.wt mouse embryonic stem cells
(PBD8) and 293T cells were treated
for 48 hr with serial applications of a
potent and well-characterized (Seiffert
et al., 2000) g-secretase inhibitor,
compound E. In the PBD8 cells, we
were able to detect the endogenous
AICD fragment of APP and saw its dis-
appearance with compound E, along
with a rise in APP CTFs (Figure 2A).
But even with this prolonged and ef-
fective inhibition of g-secretase, we
observed no decrease in neprilysin
levels in both cell lines (Figure 2A).
Quantification of neprilysin protein
levels revealed no significant differ-
ence between control and compound
E-treated cells (Figure 2B). Compound
E-treated samples were 94.3% ±
6.1% (SEM) and 107.9% ± 3.7% of ve-
hicle-treated samples for PBD8 and
293T cells, respectively. In addition,
we observed no changes in neprilysin
levels with single acute treatments of
compound E in PBD8 and 293T cells
(Figure S2).
Next, we examined prolonged g-
secretase inhibition in wt MEFs. Treat-
ment with DAPT (Dovey et al., 2001),
another well-characterized g-secre-
tase inhibitor used by Pardossi-
Piquard et al., increased APP CTFFigure 2. Neprilysin Protein Levels Are Unchanged in the Presence of g-Secretase
Inhibitors
(A) After treatment of PBD8 cells (top) and 293T cells (bottom) with compound E for 48 hr, cells
were lysed and blotted for neprilysin, APP CTFs, AICD, and GAPDH. (B) Quantifying results in
(A) revealed no statistically significant difference in neprilysin levels between vehicle (DMSO)
and compound E-treated cells in both lines. (C) Wild-typeMEFswere treated with serial, sustained
applications of DAPT for 48 hr and blotted for neprilysin, APP CTFs, and GAPDH. (D) Quantifying
neprilysin levels in (C) revealed no significant difference between vehicle (DMSO) and
DAPT-treated MEFs.
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Correspondencelevels as expected but did
not reduce neprilysin levels
(Figure 2C). DAPT-treated
cells had 117.2% ± 6.2%
of neprilysin levels versus
controls (p > 0.05) (Fig-
ure 2D). Thus, cellular
neprilysin levels were un-
affected by two distinct
g-secretase inhibitors.
Neprilysin Levels Are
Not Altered by
Introduction of the
Putative
Transcriptional
Complex of AICD,
Fe65, and Tip60
To determine whether
a transcriptional complex
consisting of AICD, Fe65,
and Tip60 (Cao and Sudhof,
2001) can regulate the tran-
scription and thus the levels
of neprilysin, as reported
(Pardossi-Piquard et al.,
2005), BD8 cells lacking
PS1 and PS2 were tran-
siently transfected with an
AICD-like construct (C60)
along with the adaptor pro-
tein Fe65 and the histone
acetyltransferase Tip60.
Levels of neprilysin, C60,
Fe65, and Tip60 were ana-
lyzed by Western blotting at 24 and
48 hr. Fe65 and Tip60 expression
levels were substantial at 24 hr and
much lower at 48 hr (Figure 3A). The
coexpression of Fe65 and Tip60 with
C60 resulted in a stabilization of C60
(Figure 3A), as reported (Kimberly
et al., 2001). Nevertheless, neprilysin
protein levels did not increase signifi-
cantly upon cointroduction of C60,
Fe65, and Tip60 at either 24 or 48 hr.
Next, we searched for C60/Fe65/
Tip60-mediated regulationof neprilysin
in wt PBD8 mouse embryonic stem
cells and wt 293T cells. Consistent
with the above results in the PS-defi-
cient BD8 cells, neprilysin levels were
unchanged upon transfection with
C60, Fe65, and Tip60 in both PBD8
(Figure 3B) and 293T cells (Figure 3C).
In the 293T cells, coexpression of all
three proteins produced a particularly
robust stabilization of C60 levels (Fig-
ure 3C, last two lanes), and yet there
was no change in neprilysin levels,
in direct contrast to the results of
Pardossi-Piquard et al. (2005). These
data indicate that neprilysin protein
levels are not regulated by a putative
transcriptional complex of C60, Fe65,
and Tip60 in the examined cell lines.
Neprilysin Levels andActivity Are
Not Affected by Lack of APP or
APLP-2 In Vivo
To examine whether APP and APLP-2
are involved in the regulation of neprily-
sin levels in vivo as reported (Pardossi-
Piquard et al., 2005), brain homoge-
nates from APP/ or APLP-2/ mice
were analyzed by both a neprilysin
activity assay andWestern blotting. Ac-
tivitywasmeasuredby hydrolysis of the
well-established fluorogenic enkepha-
lin-based substrate, N-Dansyl-D-Ala-
Gly-p-nitro-Phe-Gly (Florentin et al.,
1984). Activity corresponding to nepri-
lysin was determined by phosphorami-
don sensitivity, as used by Pardossi-
Piquard et al. (2005). Impor-
tantly, our assay provided
a specific measure of nepri-
lysin activity, as we detected
essentially no activity in brain
homogenates from neprily-
sin knockout mice (Figure
4A, insert). A time course
measuring neprilysin activity
over 40 hr yielded no signifi-
cant difference between wt
and APP/ or APLP-2/
brains (Figure 4A). We per-
formed additional measure-
ments of neprilysin activity
at the 8 hr time point and
again found no difference
between wt and knockout
samples (Figure 4B). Neprily-
sin activities in APP/ and
APLP-2/ knockout brain
homogenates were 95.3% ±
2.3% and 93.5% ± 4.2%
(SEM) of wt. Consistent
with these activity assays,
neprilysin protein levels
were indistinguishable be-
tween wt, APP/, and
APLP-2/ homogenates (Fig-
ure 4C). These data suggest
that complete lack of APP or
APLP-2 in mice reduces nei-
ther neprilysin activity nor pro-
tein levels in vivo.
Finally, to determine whether partial
inhibition of APP signaling alters nepri-
lysin levels, Mint-1 (X11a) and Mint-2
(X11b), which have been found to in-
hibit an APP-dependent transactiva-
tion assay (Biederer et al., 2002), were
transfected into both PBD8 and 293T
cells. In contrast to the results of Par-
dossi-Piquard et al., confirmed over-
expression of Mint-1 or Mint-2 did not
reduce neprilysin levels (Figure 4D).
Discussion
We obtained no evidence that neprily-
sin levels or activity are significantly
regulated by PS-mediated processing
of APP to AICD. We assessed neprily-
sin protein levels in the same PS1/
PS2-deficient mouse blastocyte and
fibroblast lines (BD8 [Hass and Yank-
ner, 2005; Zhang et al., 2000]; MEFs
[Herreman et al., 2003]) used by
Pardossi-Piquard et al. but found no
significant decrease. Instead, we
Figure 3. The Putative Transcriptional Complex Comprised
of AICD, Fe65, and Tip60 Does Not Detectably Regulate
Levels of Neprilysin
(A)PSdKO(BD8)embryonic stemcellswere transiently transfectedwith
C60, Fe65, and/or Tip60 and blotted for neprilysin, C60, Fe65, Tip60,
and GAPDH (left) and then quantified (right). (B) Wild-type (PBD8) em-
bryonic stem cells and (C) 293T cells were transiently transfected with
C60, Fe65, and/or Tip60 for 48 hr. Lysates were blotted (left panel) for
neprilysin, C60, Fe65, Tip60, and GAPDH and then quantified (right).Neuron 53, February 15, 2007 ª2007 Elsevier Inc. 481
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CorrespondenceFigure 4. In Vivo Absence of APP or APLP-2 Does Not Alter Neprilysin Levels or
Activity, and Cellular Overexpression of Mint-1 or -2 Is Also without Effect
(A and B) Phosphoramidon-inhibitable neprilysin activity was measured in whole-brain homoge-
nates from wt, APP/, and APLP-2/ mice using the substrate N-Dansyl-D-Ala-Gly-p-nitro-
Phe-Gly. (A) Time course monitoring activity from 0 to 40 hr; no statistically significant difference
between knockout (APP/ or APLP-2/) and wt. RFU, relative fluorescent units. (B) Neprilysin
activity at 8 hr in wt, APP/, and APLP-2/ mouse brains; no significant differences observed.
(C) Brain homogenates from wt (n = 4), APP/ (n = 2), and APLP-2/ (n = 2) mice were blotted
for levels of neprilysin, APP, APLP-2, and ribophorin I as a loading control. (D)Wild-type PBD8 cells
andwt 293T cells were transiently transfectedwithMint-1 orMint-2 and harvested 24 or 48 hr later,
respectively. Cells were blotted for neprilysin, Mint-1, Mint-2, and GAPDH.found substantial clonal variability in
neprilysin levels that did not correlate
with presenilin genotype. Neprilysin
levels in wt mouse embryonic stem
cells, fibroblasts, and HEK293T cells
were unchanged by a g-secretase in-
hibitor. Moreover, transfection of wt
mouse embryonic stem cells or 293T
cells with AICD alone; Fe65 plus
Tip60 alone; or AICD, Fe65, and Tip
60 together produced no change in
cellular neprilysin levels. Finally, phos-
phoramidon-sensitive neprilysin ac-
tivity in mouse brains entirely lacking
APP or APLP-2 was indistinguishable
from that in wt brains. We believe that
technical differences are unlikely to ex-
plain the fundamental discrepancies
between the two studies.
In addition to this lack of experimen-
tal confirmation, theoretical consider-
ations make such a mechanism
improbable. First, neprilysin has nu-
merous high-affinity substrates in
many tissues, including Leu-enkepha-
lin and bradykinin (reviewed in
Welches et al., 1993). Therefore, an
APP-centered mechanism to upregu-
late neprilysin would enhance degra-
dation of not only Ab but other biologi-
cally important peptides as well. APP482 Neuron 53, February 15, 2007 ª2007and PS/g-secretase are expressed
ubiquitously, so that AICD is generated
in virtually all cell types, whereas Ab is
made primarily in the brain, where b-
secretase levels are high. In the many
tissues that undergo little Ab genera-
tion, the specific feedback mechanism
of Pardossi-Piquard et al. would not be
required. Second, in all organs besides
the brain, the vast majority of APP,
APLP-1, and APLP-2 molecules un-
dergo intramembrane proteolysis by
g-secretase as the result of an initial
cleavage by a-secretase, not b-secre-
tase. Therefore, most AICD production
in organisms occurs from flux through
thea-secretase pathwaywithout yield-
ing Ab. Indeed, a-secretase can be
physiologically upregulated by numer-
ous signaling pathways in both non-
neural and neural cells, e.g., via activa-
tion of the phospholipase C/protein
kinase C pathway (Buxbaum et al.,
1993; Hung et al., 1993), and the
more such a-secretase processing of
APP occurs, the more AICD is pro-
duced but the less Ab is generated.
Thus, it seems counterintuitive that
AICD, the generation of which gener-
ally precludes Ab production, would
then stimulate neprilysin expressionElsevier Inc.to further lower Ab. Third, most mam-
mals (e.g., mice and rats) show no
detectableaccumulationofAb through-
out life, making it unlikely that there
would have been evolutionary pres-
sure for a specific mechanism to up-
regulate the neprilysin cleavage of
Ab. These various concerns about bio-
logical plausibility, together with the
lack of experimental support from our
study, make this mechanism untena-
ble at present.
Supplemental Data
The Supplemental Data for this article can be
found online at http://www.neuron.org/cgi/
content/full/53/4/479/DC1/.
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AICDs, the C-terminal fragments of
the b-amyloid precursor protein
(bAPP/APLP) that are generated by
presenilin (PS)-dependent g- and 3-
secretase activities (Pardossi-Piquard
et al., 2005). Chen and Selkoe now re-
port lack of evidence of NEP upregula-
tion by PS-dependent g-secretase. To
explore the reasons for this difference,
we have repeated several experi-
ments, conducted new experiments,
and carefully examined the data pre-
sented by Chen and Selkoe. These
analyses reveal that (1) there is signifi-
cant consensus in key experimental
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negative conclusions are overreach-
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Pardossi-Piquard et al., 2005; Figures
1A and 1B in this paper; Figures 1C
and 4C in Chen and Selkoe, 2007).
Repetition of several of our experi-
ments using different MEF cell lines
and different anti-NEP antibodies re-
veals that the results are unchanged
(Figures 1A and 1B). This argues
against an artifact arising from labora-
tory error or from differences in clones.
We have also pursued additional
experiments, both of which strongly
support the validity of our initial report.
First, we investigated NEP activity,
protein, and mRNA levels in nicastrin
knockout MEFs (NCT/), which do
not form functional presenilin com-
plexes and which have no g-secretase
activity (Yu et al., 2000). NEP expres-
sion, NEP activity, and NEP mRNA
levels were all dramatically reduced
in nicastrin knockout MEFs (NCT/)
(Pardossi-Piquard et al., 2006) (Fig-
ure 1C). However, NEP expression is
restored in these NCT/ MEFs by
bruary 15, 2007 ª2007 Elsevier Inc. 483
